Core Viewpoint - The article emphasizes the urgency of domestic substitution for "choke point" technologies in various industries due to escalating Sino-US trade tensions and the need for self-sufficiency in critical sectors [2][3]. Group 1: Research Framework & Key Industries - A comprehensive research framework is established, focusing on ten key industries: electronics, computers, communications, pharmaceuticals, medical, automotive, machinery, military, metals, and chemicals [3]. - The framework combines top-down and bottom-up approaches to assess the current state, challenges, and prospects of domestic substitution in these industries [3]. Group 2: Key Areas of Domestic Substitution - The report identifies 41 categories of critical technologies for domestic substitution across the ten industries, highlighting the importance of these areas for attracting investment [2][3]. - The analysis categorizes the difficulty of domestic substitution into five levels, ranging from extremely difficult to easy, based on factors such as market share and technological barriers [8][11]. Group 3: Electronics Industry - The semiconductor sector is highlighted as a key area for domestic substitution, with a focus on storage chips, CPUs, and GPUs, where current domestic market shares are below 5% [11][14]. - The article notes that the government is expected to increase support for key technologies in the semiconductor industry, particularly in overcoming manufacturing and equipment limitations [14][15]. Group 4: Computer Industry - The article discusses the development of a self-controlled IT ecosystem driven by policies aimed at enhancing domestic capabilities in hardware and software [19][20]. - The industrial software market is identified as a significant area for growth, with domestic companies gradually making inroads in CAD, EDA, and other software segments [20][21]. Group 5: Communication Industry - The communication equipment sector has seen significant domestic market penetration, with leading companies like Huawei and ZTE holding substantial global market shares [26][28]. - The report emphasizes the potential for domestic substitution in core communication chips, particularly in the FPGA market, which is currently dominated by foreign firms [27][31]. Group 6: Pharmaceutical and Medical Industries - The scientific instruments sector is highlighted for its low domestic substitution rates, with significant opportunities for growth driven by supportive policies [33][34]. - The article points out the challenges in the production of borosilicate glass for pharmaceuticals, indicating a need for technological advancements to reduce reliance on imports [38][40].

一、获得补助的基本情况 证券代码：688212 证券简称：澳华内镜 公告编号：2025-052 上海澳华内镜股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海澳华内镜股份有限公司（以下简称"公司"）于2025年6月30日收到政府补助款 项人民币338.00万元，属于与收益相关的政府补助款项。 二、政府补助的类型及其对公司的影响 公司根据《企业会计准则第16号——政府补助》等有关规定，确认上述事项并划分 补助类型。上述政府补助未经审计，具体的会计处理以及对公司损益的影响情况最终以 审计机构年度审计确认后的结果为准，敬请广大投资者注意投资风险。 特此公告。 上海澳华内镜股份有限公司董事会 2025年7月2日 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-051 上海澳华内镜股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 一、回购股份的基本情况 上海澳华内镜股份有限公司（以下简称"公司"）于 2025 年 1 月 3 日召开了 第二届董事会第十六次会议审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司以公司自有资金及中信银行股份有限公司上海分行提供的 股票回购专项贷款通过上海证券交易所交易系统以集中竞价交易方式回购公司股 份，所回购的股份将在未来适宜时机全部用于员工持股计划或股权激励。本次回 购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含）， 回购股份价格不超过人民币 45.00 元/股（含），回购股份期限为自董事会审议通 过回购股份方案之日起的 12 个月内。具体内容详见公司分别于 2025 年 1 月 6 日、 2025 年 1 月 9 日在上海证券交易所网站（www.sse.com.cn）上披露的《关于以集 中竞价交易方式回购股份方案的公告》（公告编号：2025-001）、《关于以集中竞价 交易方式回购股份的回购报 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-050 上海澳华内镜股份有限公司 根据《公司2025年员工持股计划（草案）》的相关规定，本员工持股计划 存续期为36个月，标的股票的锁定期为12个月，自公司公告最后一笔标的股票 过户至本员工持股计划名下之日起计算。锁定期满后，一次性解锁本持股计划 相应标的股票。 公司将根据本员工持股计划实施的进展情况，按照相关法律法规的规定及 时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 根据《关于上市公司实施员工持股计划试点的指导意见》及《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等规则的要求，现将 公司 2025 年员工持股计划实施进展情况公告如下： 根据参与对象实际认购和最终缴款的查验结果，本员工持股计划实际参与 认购的员工总数为 22 人，认购资金已全部实缴到位，最终缴纳认购资金总额为 6,000.00 万元，认购份额对应股份数量为 1,499,250 股，股票来源为公司回购 专用证券账户持有的公司 A 股普通股股票。参与本次持股计划的人员、实际认 购规模及资金来源等与公司股东大会审议通过的情况一致。 2025年6 ...

上海澳华内镜股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得补助的基本情况 上海澳华内镜股份有限公司（以下简称"公司"）于2025年6月24日收到政府补助款 项人民币230.00万元，属于与收益相关的政府补助款项。 证券代码：688212 证券简称：澳华内镜 公告编号：2025-049 二、政府补助的类型及其对公司的影响 公司根据《企业会计准则第16号——政府补助》等有关规定，确认上述事项并划分 补助类型。上述政府补助未经审计，具体的会计处理以及对公司损益的影响情况最终以 审计机构年度审计确认后的结果为准，敬请广大投资者注意投资风险。 特此公告。 上海澳华内镜股份有限公司董事会 2025年6月26日 ...

Core Viewpoint - The major shareholder of Shanghai Aohua Endoscopy Co., Ltd. has completed a share reduction plan, selling a total of 1,252,840 shares, which accounts for 0.93% of the company's total shares, primarily to meet personal funding needs [1][2][3] Group 1: Shareholder Information - Before the reduction, major shareholders Gu Kang, Gu Xiaozhou, and their controlled entity, Shanghai Xiaozhou Optoelectronics Technology Co., Ltd., held a total of 41,822,800 shares, representing 31.06% of the company's total equity [1][2] - Among these, Xiaozhou Optoelectronics held 12.59% and Gu Xiaozhou held 16.14% of the total shares [1] Group 2: Reduction Plan Implementation - The reduction plan was disclosed on May 23, 2025, with a maximum reduction of 1,252,840 shares planned to be executed within three months following the disclosure [1][2] - As of June 23, 2025, the reduction was completed, with the shares sold through centralized bidding [2][3] Group 3: Financial Details of the Reduction - The shares were sold at a price range of 45.70 to 51.90 yuan per share, resulting in a total amount of approximately 60,201,714.48 yuan [3] - After the reduction, the current shareholding of the major shareholders is 40,569,960 shares, which is 30.13% of the total shares [3]

证券代码：688212 证券简称：澳华内镜 公告编号：2025-048 上海澳华内镜股份有限公司 持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有股份的基本情况 本次减持计划实施前，顾康、顾小舟及其控制的上海小洲光电科技有限公司 （以下简称"小洲光电"）合计持有上海澳华内镜股份有限公司（以下简称"公 司"）41,822,800 股，占公司总股本的 31.06%。其中小洲光电持有公司股份 3,132,100 股，占公司总股本的 2.33%；顾康持有公司股份 16,950,200 股，占公 司总股本的12.59%；顾小舟持有公司股份21,740,500股，占公司总股本的16.14%。 上述股份来源均为公司首次公开发行前取得的股份，且已于 2024 年 11 月 15 日 起上市流通。 减持计划的实施结果情况 公司于 2025 年 5 月 23 日在上海证券交易所网站（www.sse.com.cn）披露了 《上海澳华内镜股份有限公司持股 5%以上股东减持股 ...

Core Viewpoint - The medical device sector is experiencing a significant rise, with stocks such as Haooubo hitting the daily limit of 20% increase, driven by regulatory support for high-end medical device innovation [1] Group 1: Stock Performance - Haooubo's stock surged to a 20% limit increase in the afternoon trading session [1] - Other companies like Nanwei Co., Kangwei Century, Kangzhong Medical, and Aohua Endoscopy saw increases of over 5% [1] - Additional stocks such as Libang Instruments, Chutian Technology, and Baolait also experienced upward movement [1] Group 2: Regulatory Support - The National Medical Products Administration has approved measures to optimize lifecycle regulation to support the innovation of high-end medical devices [1] - New measures aimed at fostering high-end medical device innovation are expected to be introduced [1]

Summary of Aohua Endoscopy Conference Call Company Overview - Aohua Endoscopy is experiencing short-term performance pressure due to multiple factors, including hospital procurement disruptions, slow progress in the medical equipment replacement policy, and overall industry destocking, which affects the growth rate for 2024 [2][4][11]. Key Points and Arguments - **R&D Investment**: The company places a high emphasis on R&D, maintaining a research expense ratio above 20%. The new AQ400 ultra-high-definition endoscope system, featuring a hyperspectral technology platform, is expected to provide a competitive edge [2][5]. - **Overseas Business Growth**: Aohua's overseas business is expanding rapidly, particularly in developed markets such as Europe, the Middle East, and Southeast Asia, with overseas revenue accounting for 88.9% in fiscal year 2025. There is significant potential for future growth [2][7]. - **Management Confidence**: The company is expected to reach a turning point in operations by 2026, supported by share buybacks and the launch of new products like AQ-400, alongside expansion in overseas markets [2][8][11]. - **Employee Stock Ownership Plan**: In May 2025, Aohua announced an employee stock ownership plan, offering shares to up to 22 core management personnel at a price of 40.02 yuan, reflecting management's confidence in the company's future [2][9][10]. Industry Insights - **Future Development Model**: The endoscopy industry is likely to evolve towards a three-in-one model encompassing equipment, consumables, and maintenance services, with a focus on consumables and single-use endoscopes [3][11][13]. - **Market Trends**: The endoscopy market is expected to see significant growth driven by the launch of the AQ-400, increased domestic software demand, and high growth in overseas sales. The industry is characterized by strong monopolistic tendencies, but domestic companies like Aohua are making breakthroughs in the high-end gastrointestinal endoscope market [11][12]. Additional Important Content - **Challenges in 2024 and 2025**: The company's performance in 2024 and 2025 is impacted by anti-corruption actions affecting hospital procurement, slow progress in the medical equipment replacement policy, and industry-wide destocking efforts [4][11]. - **Product Development**: Aohua is accelerating product iterations, with the AQ400 expected to launch in the second half of 2024, and ongoing development of ultrasound endoscopes and ERCP surgical robots, which are anticipated to be certified for market by 2027 [5][6][11]. - **Investment Opportunities**: Currently, Aohua is in a destocking phase but is expected to launch new products in the second half of 2025, making it a favorable investment opportunity [13][14]. This summary encapsulates the key insights from the conference call, highlighting Aohua Endoscopy's strategic focus, market dynamics, and future growth potential.

Industry Investment Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The report highlights that the domestic PFA brands are expected to enter a commercialization fast track in 2025, driven by their non-thermal ablation characteristics, shorter operation times, lower complication risks, and better long-term efficacy [5][6] - The pharmaceutical and biotechnology sector experienced a decline of 4.35% this week, underperforming the CSI 300 index by 3.9 percentage points, ranking 29th among 31 sub-industries [6][18] - The report emphasizes the importance of high-end medical device innovation, supported by recent regulatory measures aimed at optimizing lifecycle management [13][14] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 7552.12, with a 52-week high of 8490.25 and a low of 6070.89 [1] Recent Developments - Johnson & Johnson announced significant progress in PFA research at the HRS2025 conference, showcasing three key PFA products with excellent safety and efficacy profiles [4][5] - The report notes that six domestic brands have received approval for PFA technology, marking a significant step towards commercialization [5] Subsector Performance - All sub-sectors within the pharmaceutical and biotechnology industry experienced declines this week, with the largest drop in the other biological products sector at 6.7% [6][23] - The report provides a detailed breakdown of weekly performance across various sub-sectors, indicating a general trend of retraction [6][24] Recommended and Beneficiary Stocks - Recommended stocks include innovative pharmaceutical companies such as Xinda Biopharma and Kangfang Biopharma, as well as medical device firms like Yingke Medical and Maipu Medical [7][29] - Beneficiary stocks in the innovative drug sector include Zai Lab, Yifan Biopharma, and others, while the medical device sector includes companies like Mindray Medical and Aohua Endoscopy [7][29] Regulatory Insights - The report discusses the approval of measures to support high-end medical device innovation, which includes optimizing special approval processes and enhancing communication mechanisms [13][14] - The report suggests that the implementation of these measures will significantly benefit high-tech medical devices, including AI-assisted diagnostic tools [14][28]